Q1 2025 MDxHealth SA Earnings Call Transcript
Key Points
- MDxHealth SA (MDXH) achieved a 22% revenue growth in Q1 2025, marking the 16th consecutive quarter of 20% or greater revenue growth.
- The company reported a significant increase in tissue-based test volumes, with a 41% growth over the prior year period.
- Gross profit for the quarter increased by 29%, with gross margins improving to 63.8% from 60.8% in Q1 2024.
- MDxHealth SA (MDXH) has not expanded its sales organization, yet continues to achieve growth, indicating strong leverage from its existing sales channels.
- The company is on track to achieve positive adjusted EBITDA in Q2 2025, reflecting strong financial management and operational efficiency.
- Net loss increased by 8% to $9.2 million, primarily due to non-cash fair value adjustments.
- Operating expenses grew by 8%, driven by increased clinical studies, stock-based compensation, and scale.
- The liquid-based test segment showed a lower growth rate of 9% compared to the tissue-based segment.
- Cash and cash equivalents were reduced to $37.7 million after a $28 million earnout payment to Exact Sciences.
- The company faces inherent risks and uncertainties, as highlighted in their forward-looking statements and SEC filings.
Good day and welcome to the MDxHealth first quarter 2025 earnings conference call. (Operator Instructions)
I would now like to turn the conference over to Mr. John Fraunces with Lifesci Advisors. Please go ahead.
Good afternoon and thank you for joining us for the MDxHealth first quarter 2025 earnings conference call. Joining me on today's call are Michael McGarrity, Chief Executive Officer, and Ron Kalpas, Chief Financial Officer.
Before we begin, I would like to remind everyone that the company will be making forward-looking statements during today's call, whether in prepared remarks or during the Q&A session. These forward-looking statements are subject to inherent risks and uncertainties. These risks and uncertainties are detailed in the risk factor section of the company's filings with the Securities and Exchange Commission, specifically in the company's annual report on Form 20.
I'll now turn the call over to Michael McGarrity, Chief Executive Officer.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
